Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A Controlled Clinical Trial

Arthritis & Rheumatism

Volumn 28, Issue 7, 1985, Pages 721-730

  Williams, H James ^a   Willkens, Robert F ^b   Samuelson, Cecil O ^a   Alarcón, Graciela S ^c   Guttadauria, Maria ^d   Yarboro, Cheryl ^e   Polisson, Richard P ^f   Weiner, Steven R ^g   Luggen, Michael E ^h   Billingsley, Lynn M ⁱ   Dahl, Stephen L ^a   Egger, Marlene J ^a   Reading, James C ^a   Ward, John R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXTROPROPOXYPHENE; LIVER ENZYME; METHOTREXATE; PARACETAMOL; PLACEBO; PREDNISONE;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM; DISEASE ACTIVITY; DRUG EFFICACY; DRUG THERAPY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INTOXICATION; JOINT; LIVER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MOUTH; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STOMATITIS; THERAPY;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; ASPIRIN; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED;

EID: 0021794435     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780280702     Document Type: Article

References (40)

1. Methotrexate
2. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis
3. Methotrexate therapy in psoriatic arthritis
4. The pharmacology and clinical use of methotrexate
5. The mechanisms of action of the folate antagonists in man
6. Therapeutic suppression of tissue reactivity. II. Effects of aminopterin in rheumatoid arthritis and psoriasis
7. Low dose pulse methotrexate therapy of rheumatoid arthritis
8. Methotrexate in the treatment of rheumatoid arthritis
9. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Symposium on Oral Gold Therapy in Rheumatoid Arthritis, August 1982
10. Weekly intravenous methotrexate in the treatment of rheumatoid arthritis
11. Low dose methotrexate in rheumatoid arthritis
12. Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature
13. Oral methotrexate therapy in rheumatoid arthritis (abstract)
14. Pulse methotrexate therapy for rheumatoid arthritis: a double‐blind, crossover study (abstract)
15. A double‐blind placebo controlled short‐term trial of parenteral methotrexate in rheumatoid arthritis (abstract)
16. A prospective randomized controlled trial of low dose pulse methotrexate in rheumatoid arthritis (abstract)
17. 1958 revision of diagnostic criteria for rheumatoid arthritis
18. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)
19. Therapeutic criteria in rheumatoid arthritis
20. A seven‐day variability study of 499 patients with peripheral rheumatoid arthritis
21. Proximal interphalangeal joint measurement by arthrocircameter
22. Assessment for clinical trials
23. Preliminary criteria for clinical remission in rheumatoid arthritis
24. Multiple comparisons in clinical trials: how far should we go? (abstract)
25. Methotrexate: a perspective of its use in the treatment of rheumatic diseases
26. Azathioprine compared with methotrexate in the treatment of rheumatoid arthritis—results of a double‐blind, 24 week trial (abstract)
27. Methotrexate for psoriasis: a new therapeutic schedule
28. Systemic chemotherapy for psoriasis: a national survey
29. Methotrexate guidelines: revised
30. Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis
31. Liver damage due to methotrexate in patients with psoriasis
32. HLA antigens in methotraexate‐induced liver cirrhosis
33. Psoriasis‐liver methotrexate interactions
34. Hepatotoxicity of long‐term methotrexate therapy for psoriasis
35. Methotrexate hepatotoxicity in psoriasis
36. Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment
37. Effects of methotrexate on the liver in psoriasis
38. Selection and combination of outcome measures